372 related articles for article (PubMed ID: 23811849)
1. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists.
Yamazaki T; Hannani D; Poirier-Colame V; Ladoire S; Locher C; Sistigu A; Prada N; Adjemian S; Catani JP; Freudenberg M; Galanos C; André F; Kroemer G; Zitvogel L
Cell Death Differ; 2014 Jan; 21(1):69-78. PubMed ID: 23811849
[TBL] [Abstract][Full Text] [Related]
2. TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells.
Fang H; Ang B; Xu X; Huang X; Wu Y; Sun Y; Wang W; Li N; Cao X; Wan T
Cell Mol Immunol; 2014 Mar; 11(2):150-9. PubMed ID: 24362470
[TBL] [Abstract][Full Text] [Related]
3. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
[TBL] [Abstract][Full Text] [Related]
4. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.
Apetoh L; Ghiringhelli F; Tesniere A; Criollo A; Ortiz C; Lidereau R; Mariette C; Chaput N; Mira JP; Delaloge S; André F; Tursz T; Kroemer G; Zitvogel L
Immunol Rev; 2007 Dec; 220():47-59. PubMed ID: 17979839
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of HMGB1 A-box reduced lipopolysaccharide-induced intestinal inflammation via HMGB1/TLR4 signaling in vitro.
Wang FC; Pei JX; Zhu J; Zhou NJ; Liu DS; Xiong HF; Liu XQ; Lin DJ; Xie Y
World J Gastroenterol; 2015 Jul; 21(25):7764-76. PubMed ID: 26167076
[TBL] [Abstract][Full Text] [Related]
6. Signaling of high mobility group box 1 (HMGB1) through toll-like receptor 4 in macrophages requires CD14.
Kim S; Kim SY; Pribis JP; Lotze M; Mollen KP; Shapiro R; Loughran P; Scott MJ; Billiar TR
Mol Med; 2013 May; 19(1):88-98. PubMed ID: 23508573
[TBL] [Abstract][Full Text] [Related]
7. Human tumor cells killed by anthracyclines induce a tumor-specific immune response.
Fucikova J; Kralikova P; Fialova A; Brtnicky T; Rob L; Bartunkova J; Spísek R
Cancer Res; 2011 Jul; 71(14):4821-33. PubMed ID: 21602432
[TBL] [Abstract][Full Text] [Related]
8. High mobility group box protein 1 (HMGB1)-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor.
Hreggvidsdóttir HS; Lundberg AM; Aveberger AC; Klevenvall L; Andersson U; Harris HE
Mol Med; 2012 Mar; 18(1):224-30. PubMed ID: 22076468
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses.
Davis MB; Vasquez-Dunddel D; Fu J; Albesiano E; Pardoll D; Kim YJ
Clin Cancer Res; 2011 Jun; 17(12):3984-92. PubMed ID: 21543518
[TBL] [Abstract][Full Text] [Related]
10. HMGB1 was negatively regulated by HSF1 and mediated the TLR4/MyD88/NF-κB signal pathway in asthma.
Shang L; Wang L; Shi X; Wang N; Zhao L; Wang J; Liu C
Life Sci; 2020 Jan; 241():117120. PubMed ID: 31825792
[TBL] [Abstract][Full Text] [Related]
11. High-mobility group box 1 protein contributes to the immunogenicity of rTcdB-treated CT26 cells.
Gu H; Liu J; Chen S; Qi H; Shi K; Li S; Ma Y; Wang J
Acta Biochim Biophys Sin (Shanghai); 2018 Sep; 50(9):921-928. PubMed ID: 30052706
[TBL] [Abstract][Full Text] [Related]
12. Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with Mycobacterium tuberculosis heparin-binding hemagglutinin, a novel TLR4 agonist.
Jung ID; Jeong SK; Lee CM; Noh KT; Heo DR; Shin YK; Yun CH; Koh WJ; Akira S; Whang J; Kim HJ; Park WS; Shin SJ; Park YM
Cancer Res; 2011 Apr; 71(8):2858-70. PubMed ID: 21368092
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of ATP secretion during immunogenic cell death.
Martins I; Wang Y; Michaud M; Ma Y; Sukkurwala AQ; Shen S; Kepp O; Métivier D; Galluzzi L; Perfettini JL; Zitvogel L; Kroemer G
Cell Death Differ; 2014 Jan; 21(1):79-91. PubMed ID: 23852373
[TBL] [Abstract][Full Text] [Related]
14. MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant.
Orr MT; Duthie MS; Windish HP; Lucas EA; Guderian JA; Hudson TE; Shaverdian N; O'Donnell J; Desbien AL; Reed SG; Coler RN
Eur J Immunol; 2013 Sep; 43(9):2398-408. PubMed ID: 23716300
[TBL] [Abstract][Full Text] [Related]
15. Abnormal expression of Toll-like receptor 4 is associated with susceptibility to ethanol-induced gastric mucosal injury in mice.
Ye HH; Hua R; Yu L; Wu KJ; Fei SJ; Qin X; Song Y; Cao JL; Zhang YM
Dig Dis Sci; 2013 Oct; 58(10):2826-39. PubMed ID: 23744365
[TBL] [Abstract][Full Text] [Related]
16. MD-2 is required for disulfide HMGB1-dependent TLR4 signaling.
Yang H; Wang H; Ju Z; Ragab AA; Lundbäck P; Long W; Valdes-Ferrer SI; He M; Pribis JP; Li J; Lu B; Gero D; Szabo C; Antoine DJ; Harris HE; Golenbock DT; Meng J; Roth J; Chavan SS; Andersson U; Billiar TR; Tracey KJ; Al-Abed Y
J Exp Med; 2015 Jan; 212(1):5-14. PubMed ID: 25559892
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of HMGB1 improves necrotizing enterocolitis by inhibiting NLRP3 via TLR4 and NF-κB signaling pathways.
Yu R; Jiang S; Tao Y; Li P; Yin J; Zhou Q
J Cell Physiol; 2019 Aug; 234(8):13431-13438. PubMed ID: 30618088
[TBL] [Abstract][Full Text] [Related]
18. Cross-Presentation of the Oncofetal Tumor Antigen 5T4 from Irradiated Prostate Cancer Cells--A Key Role for Heat-Shock Protein 70 and Receptor CD91.
Salimu J; Spary LK; Al-Taei S; Clayton A; Mason MD; Staffurth J; Tabi Z
Cancer Immunol Res; 2015 Jun; 3(6):678-88. PubMed ID: 25678582
[TBL] [Abstract][Full Text] [Related]
19. The protective effect of dexmedetomidine on LPS-induced acute lung injury through the HMGB1-mediated TLR4/NF-κB and PI3K/Akt/mTOR pathways.
Meng L; Li L; Lu S; Li K; Su Z; Wang Y; Fan X; Li X; Zhao G
Mol Immunol; 2018 Feb; 94():7-17. PubMed ID: 29241031
[TBL] [Abstract][Full Text] [Related]
20. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies.
Apetoh L; Tesniere A; Ghiringhelli F; Kroemer G; Zitvogel L
Cancer Res; 2008 Jun; 68(11):4026-30. PubMed ID: 18519658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
